ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas2026
Set binding factor 1 (SBF1/MTMR5) as a potential novel target in colorectal cancer: an exploratory immunohistochemical and bioinformatics study.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide, and dysregulation of phosphoinositides signaling pathways plays a critical role in its pathogenesis. The involvement of Set Binding Factor 1 (SBF1; MTMR5), a pseudophosphatase of the myotubularin family in CRC, remains unexplored. This study compiled experimental and bioinformatics approaches to investigate the expression and potential relevance of SBF1 in CRC. Immunohistochemical analysis was performed on CRC tissue specimens and corresponding normal adjacent tissues (NAT), with estimation of SBF1 staining followed by statistical comparison. In parallel, bioinformatics assessed gene ontology and protein-protein interactions, and open CRC datasets were analyzed to assess SBF1 alterations, expression profiles, and survival associations. The results demonstrated a significant overexpression of SBF1 in CRC tissues compared with NAT. Bioinformatics revealed SBF1 as a partner within a functional network enriched in phosphoinositide metabolism. Bioinformatics identified SBF1 genetic alterations in approximately 5% of cases, and survival analysis indicated that wild-type SBF1 could be an unfavorable prognostic marker, as reflected by hazard assessment. Collectively, these findings provided the first experimental evidence that SBF1 is overexpressed in CRC and suggest that it may represent an unrecognized component of phosphoinositide related pathways involved in colorectal tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.